THTX - Theratechnologies Inc.
IEX Last Trade
1.285
0.005 0.389%
Share volume: 4,379
Last Updated: Fri 30 Aug 2024 09:59:25 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$1.28
0.01
0.39%
Fundamental analysis
6%
Profitability
0%
Dept financing
16%
Liquidity
44%
Performance
0%
Performance
5 Days
-3.40%
1 Month
-9.86%
3 Months
2.40%
6 Months
-11.11%
1 Year
29.96%
2 Year
-85.12%
Key data
Stock price
$1.28
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.88 - $3.29
52 WEEK CHANGE
$0.36
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/24/2024
Company detail
CEO: Paul Lévesque
Region: US
Website: theratech.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: theratech.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Theratechnologies Inc. focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV.
Recent news